Comparison · NCT00924170-sae
Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC vs All Other Patients: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC vs All Other Patients: serious adverse events. Trial comparisons, record NCT00924170-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00924170-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.7 | 0.397 | 0.892 | wilson | |
| Risk in group 2 | 0.75 | 0.409 | 0.929 | wilson | |
| Risk difference, group 1 minus group 2 | -0.05 | -0.402 | 0.341 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.933 | 0.528 | 1.65 | log | |
| Odds ratio, group 1 over group 2 | 0.778 | 0.0957 | 6.32 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC than on All Other Patients | 20 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC | Leukemic patients receiving LMB-2 and at least 25+250 mg/m\^2 fludarabine and cyclophosphamide; CF03-CF05, CF07-CF10, and CF12-CF14. | 7 | 10 | EG000 |
| Group 2 | All Other Patients | Patients CF01-CF02, CF06, CF11, and CF15-CF18. This is a mixture of patients who did not receive LMB-2, who had lymphoma-type adult T-cell leukemia, and who received 20+250 mg/m\^2 of fludarabine cyclophosphamide (FC). | 6 | 8 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 7 years and 12 days
Source ClinicalTrials.gov
Trial
- Title
- Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
- NCT number
- NCT00924170
- Phases
- PHASE1, PHASE2
- Conditions
- Adult T-Cell Leukemia (ATL)
- Interventions
- LMB-2, Fludarabine, Cyclophosphamide
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2017-09-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00924170?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00924170-sae